A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Read more about A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Read more about Clinically localized prostate cancer in 2017: A review of comparative effectiveness.
What is the best way not to treat prostate cancer? Read more about What is the best way not to treat prostate cancer?
Utility of novel androgen receptor therapies in the real world: A nuanced approach. Read more about Utility of novel androgen receptor therapies in the real world: A nuanced approach.
Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Read more about Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy.
Approaches to minimize castration in the treatment of advanced prostate cancer. Read more about Approaches to minimize castration in the treatment of advanced prostate cancer.
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. Read more about Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Read more about Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
Agent Orange and long-term outcomes after radical prostatectomy. Read more about Agent Orange and long-term outcomes after radical prostatectomy.
Concurrent urologic and palliative care after cystectomy for treatment of muscle-invasive bladder cancer. Read more about Concurrent urologic and palliative care after cystectomy for treatment of muscle-invasive bladder cancer.
